Future directions in the second-line treatment of non-small cell lung cancer

Seminars in Oncology

Volumn 33, Issue SUPPL. 1, 2006, Pages 45-51

  Rosell, Rafael ^a   Cecere, Fabiana ^a,b   Cognetti, Francesco ^b   Cuello, Mauricio ^a,c   Sanchez, Jose Miguel ^a   Taron, Miquel ^a   Reguart, Noemi ^a   Jablons, David ^d  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOPLATIN; CISPLATIN; CPG 7909; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; K RAS PROTEIN; LYMPHOCYTE DEFINED TUMOR ANTIGEN; MELANOMA ANTIGEN 3; MUCIN 1; NAVELBINE; OLIGODEOXYNUCLEOTIDE; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN P53; RECOMBINANT EPIDERMAL GROWTH FACTOR; SMALL INTERFERING RNA; TAXANE DERIVATIVE; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TRANSCRIPTION FACTOR SOX4; TUMOR ANTIGEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT PROTEIN;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DNA ADDUCT; DNA MODIFICATION; DNA REPAIR; DRUG SCREENING; DRUG TARGETING; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC SCREENING; HUMAN; INJECTION SITE REACTION; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; SIGNAL TRANSDUCTION; STEM CELL; TARGET CELL; TOXICITY; TREATMENT RESPONSE; TUMOR CELL;

EID: 32044444082     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.12.002     Document Type: Article

References (64)

1. D.J. Maslyar, T.M. Jahan, D.M. Jablons Mechanisms of and potential treatment strategies for metastatic disease in non-small cell lung cancer Semin Thorac Cardiovasc Surg 16 2004 40 50
2. L.A. Garraway, H.R. Widlund, M.A. Rubin Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma Nature 436 2005 117 122
3. R. Rosell, G. Scagliotti, K. Danenberg Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer Oncogene 22 2003 3548 3553
4. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer A meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899 909
5. T. Winton, R. Livingston, D. Johnson Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597
6. S. Rodenhuis, M.L. Van de Wetering, W.J. Mooi Mutational activation of the K-ras oncogene A possible pathogenetic factor in adenocarcinoma of the lung N Engl J Med 317 1987 929 935
7. R.J. Slebos, R.E. Kibbelaar, O. Dalesio K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung N Engl J Med 323 1990 561 565
8. R. Rosell, S. Li, Z. Skacel Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients Oncogene 8 1993 2407 2412
9. R. Rosell, J. Gómez-Codina, C. Camps A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer N Engl J Med 330 1994 153 158
10. J. Takamizawa, H. Konishi, K. Yanagisawa Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival Cancer Res 64 2004 3753 3756
11. S.M. Johnson, H. Grosshans, J. Shingara RAS is regulated by the let-7 microRNA family Cell 120 2005 635 647
12. W. Pao, T.Y. Wang, G.J. Riely Kras mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 57 61
13. R.O. Dillman, S.L. Seagren, K.J. Propert A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer N Engl J Med 323 1990 940 945
14. N. Zeng-Rong, J. Paterson, L. Alpert Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy Cancer Res 55 1995 4760 4764
15. C.H. Bosken, Q. Wei, C.I. Amos An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer J Natl Cancer Inst 94 2002 1091 1099
16. P.J.M. Van de Vaart, J. Belderbos, D. De Jong DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy Int J Cancer 89 2000 160 166
17. K. Kelly, J. Crowley, P.A. Bunn Jr Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer A Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
18. J.H. Schiller, D. Harrington, C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
19. T. Hoang, R. Xu, J.H. Schiller Clinical model to predict survival in chemonaive patients with non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data J Clin Oncol 23 2005 175 183
20. R.V.N. Lord, J. Brabender, D. Gandara Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer Clin Cancer Res 8 2002 2286 2291
21. M. Cobo, D. Isla, J. Sanchez ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p) Lung Cancer 49 2005 S32 abstr O-089
22. G. Giaccone, R.S. Herbst, C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer A phase III trial-INTACT 1 J Clin Oncol 22 2004 777 784
23. R.S. Herbst, G. Giaccone, J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer A phase III trial-INTACT 2 J Clin Oncol 22 2004 785 794
24. R.S. Herbst, D. Prager, R. Hermann TRIBUTE A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 2005 5892 5899
25. F. Weber, K. Fukino, T. Sawada Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors Br J Cancer 92 2005 1922 1926
26. J.E. Quinn, R.D. Kennedy, P.B. Mullan BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis Cancer Res 63 2003 6221 6228
27. M. Taron, R. Rosell, E. Felip BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer Hum Mol Genet 13 2004 2443 2449
28. R. Rosell, M. Taron, G. Altavilla Chemotherapy treatment options for non-small cell lung cancer. Business Briefing Eur Oncol Rev 2005 Available at: http://www.touchbriefings.com
29. N. Hanna, F.A. Shepherd, F.V. Fossella Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
30. H.J. Lenz, C.G. Leichman, K.D. Danenberg Thymidilate synthase mRNA level in adenocarcinoma of the stomach A predictor for primary tumor response and overall survival J Clin Oncol 14 1995 176 182
31. C. Hubbert, A. Guardiola, R. Shao HDAC6 is a microtubule-associated deacetylase Nature 417 2002 455 458
32. L. Crino, A.M. Mosconi, G. Scagliotti Gemcitabine as second-line treatment for advanced non-small cell lung cancer A phase II trial J Clin Oncol 17 1999 2081 2085
33. R. De la Peñas, C. Camps, G. Lopez-Vivanco Pharmacogenomic study of docetaxel and cisplatin in patients with non-small-cell lung cancer (NSCLC) stages IIIb (with malignant pleural effusion) and IV Lung Cancer 49 2005 S37 abstr O-105
34. M.R. Spitz, X. Wu, Y. Wang Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients Cancer Res 61 2001 1354 1357
35. O. Popanda, T. Schattenberg, C.T. Phong Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer Carcinogenesis 25 2004 2433 2441
36. H. Cortes-Funes, C. Gomez, R. Rosell Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients Ann Oncol 16 2005 1081 1086
37. M. Taron, Y. Ichinose, R. Rosell Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas Clin Cancer Res 11 2005 5878 5885
38. K.M. Hege, D.P. Carbone Lung cancer vaccines and gene therapy Lung Cancer 41 2003 S103 S113
39. J.R. Yannelli, J.M. Wroblewski On the road to a tumor cell vaccine 20 years of cellular immunotherapy Vaccine 23 2004 97 113
40. Y.T. Chen, M.J. Scanlan, U. Sahin A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening Proc Natl Acad Sci U S A 94 1997 1914 1918
41. W. Sienel, C. Varwerk, A. Linder Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer Results of a multi-center study Eur J Cardiothorac Surg 25 2004 131 134
42. D. Atanackovic, N.K. Altorki, E. Stockert Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients J Immunol 172 2004 3289 3296
43. R.S. Friedman, C.S. Bangur, E.J. Zasloff Molecular and immunological evaluation of the transcription factor SOX-4 as a lung tumor vaccine antigen J Immunol 172 2004 3319 3327
44. C. Manegold, G. Leichman, D. Gravenor Phase II randomized trial adding a toll-like receptor 9 agonist (ProMune) to first line chemotherapy shows improved response in advanced non-small-cell lung cancer Lung Cancer 49 2005 S80 abstr PD-046
45. C. Butts A multicenter phase IIB randomized study of the liposomal MUC1 vaccine L-BLP25 for immunotherapy of advanced non-small-cell lung cancer (NSCLC) Lung Cancer 49 2005 S30 abstr O-083
46. G. Gonzalez, T. Crombet, F. Torres Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy Ann Oncol 14 2003 461 466
47. R. Eager, J. Nemunaitis GM-CSF gene-transduced tumor vaccines Mol Ther 12 2005 18 27
48. J. Nemunaitis GVAX (GMCSF gene modified tumor vaccine) in advanced stage non small cell lung cancer J Control Release 91 2003 225 231
49. R. Salgia, T. Lynch, A. Skarin Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small cell lung carcinoma J Clin Oncol 21 2003 624 630
50. J. Nemunaitis, D. Sterman, D. Jablons Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small cell lung cancer J Natl Cancer Inst 96 2004 326 331
51. J. Schiller, J. Nemunaitis, H. Ross A phase 2 randomized study of GM-CSF gene-modified autologous tumor vaccine (CG8123) with and without low-dose cyclophosphamide in advanced stage non-small-cell lung cancer (NSCLC) Lung Cancer 49 2005 S91 abstr PD-081
52. S.G. Swisher, J.A. Roth, J. Neumanaitis Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer J Natl Cancer Inst 91 1999 763 771
53. B. Neyns, M. Noppen Intratumoral gene therapy for non-small cell lung cancer Current status and future directions Monaldi Arch Chest Dis 59 2003 287 295
54. M. Dean, T. Fojo, S. Bates Tumour stem cells and drug resistance Nat Rev Cancer 5 2005 275 284
55. T. Reya, H. Clevers Wnt signalling in stem cells and cancer Nature 434 2005 843 850
56. S.K. Singh, C. Hawkins, I.D. Clarke Identification of human brain tumour initiating cells Nature 432 2004 396 401
57. B.Y. Liu, S.P. McDermott, S.S. Khwaja The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells Proc Natl Acad Sci U S A 101 2004 4158 4163
58. B. He, R.N. Barg, L. You Wnt signalling in stem cells and non-small cell lung cancer Clin Lung Cancer 7 2005 54 60
59. B. He, Y. Liang, L. You A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells Neoplasia 6 2004 7 14
60. J. Mazieres, B. He, L. You Wnt inhibitor factor-1 is silenced by promoter hypermethylation in human lung cancer Cancer Res 64 2004 4717 4720
61. B. He, A.Y. Lee, S. Dadfarmay Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in β-catenin-deficient human mesothelioma cells Cancer Res 65 2005 743 748
62. K. Uematsu, B. He, L. You Activation of the Wnt pathway in non-small cell lung cancer Evidence of dishevelled overexpression Oncogene 22 2003 7218 7221
63. K. Uematsu, S. Kanazawa, L. You Wnt pathway activation in mesothelioma Evidence of dishevelled overexpression and transcriptional activity of β-catenin Cancer Res 63 2003 4547 4551
64. L. You, B. He, K. Uematsu Inhibition of Wnt-1 signalling induces apoptosis in β-catenin-deficient mesothelioma cells Cancer Res 64 2004 3474 3478